Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene to Participate in Three Upcoming Investor Conferences in May/June

CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi...

2022-05-06 08:30 3561

Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

SHANGHAI and HONG KONG, April 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2022-04-29 22:30 3654

Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018

* Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small mol...

2022-04-27 08:30 2984

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

The company will present the preclinical data of five novel drug candidates at AACR 2022 (onApril 8...

2022-04-11 08:30 3996

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Antengene's Pivotal "MARCH" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

- Results showed an overall response rate (ORR) of 29.3% for all treated patients. - Consistent res...

2022-04-06 20:03 4254

Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

* This study is the third ATG-016 study to be conducted in China. * Study highlights Antengene's...

2022-03-30 09:00 3305

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates

SHANGHAI and HONG KONG, March 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2022-03-18 22:12 7159

Antengene Announces IND Approval in China for the Phase I Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

- The novel bispecific antibody ATG-101 is Antengene's first in house developed molecule with glob...

2022-03-10 08:52 4278

Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting

* Posters Showcase Early-Stage Clinical and Preclinical Pipeline. * Focus on ATG-037, ATG-018, A...

2022-03-09 20:00 4817

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed an...

2022-03-09 19:08 3682

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

SHANGHAI and HONG KONG, March 2, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2022-03-02 08:47 4065

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

SHANGHAI and HONG KONG, Feb. 7, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2022-02-07 08:30 3843

Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2022-01-05 12:50 4174

Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

SHANGHAI and HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2021-12-30 09:51 4551

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI and HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-12-20 11:01 4754

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI AND HONG KONG, Dec. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-12-20 10:56 3379

Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

SHANGHAI and HONG KONG, Dec. 17, 2021 /PRNewswire/ -- Antengene Corporation Limited (the "Company" ...

2021-12-17 22:27 6047

Antengene and XtalPi Announce AI-Driven R&D Collaboration

SHANGHAI and HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2021-12-16 16:30 4010

Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

SHANGHAI and HONG KONG, Dec. 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-12-14 18:00 3666

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

* ATG-017 is an oral small molecule ERK1/2 inhibitor; Opdivo® is aPD-1 checkpoint inhibitor * C...

2021-12-13 08:30 3686